This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Healthcare Europe

Press Releases

Take a look at a selection of our recent media coverage:

Antibiotic use in midlife women for at least two months associated with small decrease in cognition scores

8th April 2022

Antibiotic use among midlife women for two months and longer is linked to lower cognition scores when assessed approximately 7 years later

Antibiotic use for at least two months among midlife women has been found to be associated with a minor, but significant reduction in overall cognition scores when re-assessed approximately 7 years later. This was the conclusion of an analysis of women in the Nurses’ Health Study II by researchers from the Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, US.

Research has increasingly pointed to a connection between the gut-brain axis, linking emotional and cognitive centres of the brain with intestinal functions and especially the influence of the gut microbiota in these interactions. In fact, it is already established that there are microbiome composition links with mental health including quality of life and depression.

Antibiotic use negatively affect the balance of the gut microbiota and in fact, some evidence suggests that in women, use of antibiotics (for ≥ 2 months) in late adulthood is associated with a significant increased risk of cardiovascular disease. Nevertheless, whether antibiotic use, which affects microbiome diversity, might also have a detrimental impact upon cognition is unclear although early exposure to antibiotics in the first 24 months of life may be associated with detrimental neuro-developmental outcomes, 11 years later. There is also some data showing how gut microbial alterations may also be associated with Alzheimer’s disease.

For the present study, the US team examined midlife antibiotic use among women and subsequent cognitive function which was assessed 7 years later. They used data from the Nurses’ Health Study II, which is an on-going prospective cohort study and in which participants complete detailed lifestyle, medication and health-related questionnaires every 2 years. In 2009, participants were asked to report on their total duration of antibiotic use into 7 categories, ranging from none to > 3 years, over the preceding 4 years. Since at the time, the mean age of participants was 54.7 years, this was called midlife antibiotic use. Approximately 7 years after 2009, the researchers administered the CogState battery which assesses global cognition, psychomotor function, learning and working memory. Antibiotic use was categorised as none, 1 – 14 days, 15 days to 2 months and 2 months+.

Regression analysis was undertaken to assess the relationship between the use of antibiotics and cognitive decline, adjusting for several factors including body mass index, smoking status, educational attainment.

Antibiotic use and cognition scores

A total of 14,542 women with a mean age of 61.7 years completed the cognitive testing and were included in the analysis.

Compared to non-antibiotic users, women using antibiotics for at least 2 months or longer, had mean global cognition scores that were lower by -0.08 standard units (95% CI -0.12 to – 0.073 p for trend = 0.002) in fully adjusted models. Similarly, for psychomotor speed and attention, the mean scores were -0.10 (95% CI -0.16 to -0.04, p = 0.004) and -0.06 (95% CI -0.11 to – 0.01, p = 0.03) for learning and working memory.

The authors concluded that chronic antibiotic use in midlife were associated with minor decreases in cognitive scores when assessed approximately 7 years later.

Mehta RS et al. Association of midlife antibiotic use with subsequent cognitive function in women PLoS One 2022

Physical activity slows cognitive decline in those with high tau levels

13th August 2021

Among individuals with high tau levels, undertaking physical activity led to a much lower decline in cognitive function over time.

Tau is a microtubule-associated protein in neurons but aberrant assembly of the protein is present in neurodegenerative disorders. However, while abnormalities in the assembly of tau appear to be strongly associated with the development of disorders such as dementia and Alzheimer’s disease, it remains unclear how this links with upstream events. Tau levels can now be measured in blood and higher levels have been associated with cognitive decline and with the development of Alzheimer’s disease. Increased physical exercise improves blood flow to the brain and greater levels of activity appear to be associated with a reduced risk of developing degenerative conditions such as Alzheimer’s disease. Given that tau levels can serve as a biomarker of cognitive decline what remains uncertain is whether it is possible to correlate changes cognition with preventative strategies such as physical exercise over time. This was the aim of a study by a team from the Rush Institute for Healthy Aging, Rush University, Chicago, US. They used data contained within the Chicago Health and Aging Project (CHAP), which is a population-based cohort of African Americans and White participants, 65 years and older. The CHAP study is designed to explore chronic common health problems, especially risk factors for incident Alzheimer’s disease.

For the present study, the researchers included participants older than 65 years and without Alzheimer’s disease at baseline. Samples of tau were measured between 1994 and 2012 and frozen and later assayed. The team collected information on the levels of physical activity of participants and categorised this as either low, medium and high. Medium activity was where it was for less than 150 minutes per week, or high, if greater than 150 minutes. Low levels indicated that participants did not undertake any physical activity. Tau blood levels were also measured and considered as either high (> 0.40 pg/ml) or low (<0.40 pg/ml) based on earlier data suggesting a higher rate of cognitive decline in those with levels greater than 0.40. The main outcome of the study was global cognitive function based on a battery of tests and the measurement duration for the study was 18 years.

A total of 1159 participants were included with a mean age of 77.4 years (63% female) and with 60% of African American descent. In participants with a high tau level (> 0.40 pg/ml) and a medium level of physical activity, there was a 58% slower rate of cognitive decline per year compared to those undertaking little physical activity. Similarly, in those with high tau levels and high physical activity, the rate of cognitive decline was 41% slower than those with low activity. Even where tau levels were low, medium physical activity was associated with a 2% slower rate of decline and a 27% lower rate for those with high physical activity.

The authors concluded that physical activity was associated with a much slower decline in cognitive function among those with both low and high tau levels and that this could be easily measured with tau levels. They called for future studies to examine the relationship between tau levels and other forms (i.e., strength training) of physical activity.

Desai P et al. Longitudinal Association of Total Tau Concentrations and Physical Activity with Cognitive Decline in a Population Sample. JAMA Netw Open 2021

Better glucose control improves cognitive function in type 2 diabetes

23rd October 2020

Type 2 diabetes affects a large number of patients and can lead to serious adverse health outcomes including cardiovascular disease, retinopathy, nephropathy and neuropathy.

Patients with type 2 diabetes have also been shown to have an increased the risk of cognitive impairment and dementia. Achievement of good glycaemic control is associated with a reduction in the risk of many of adverse health outcomes and this can be attained through weight loss, but the evidence for an improvement in cognitive impairment is currently mixed. In this study, researchers from several centres in the US have reported on the results from the Action for Health in Diabetes (look AHEAD) study which suggests that it is glycaemic control, rather than weight reduction, which has the greatest impact on cognitive functioning. The look AHEAD study is a single blind, randomised trial that recruited 5145 individuals during 2001 to 2004 with a BMI >25kg/m2, a HbA1c < 11%, triglycerides < 600mg/dl and a systolic/diastolic blood pressure < 160/100 mmHg. Participants were randomised to either an intensive lifestyle intervention (ILI) or a diabetes support and education (DSE) control group and the interventions continued until 2012, which was an average of 9.9 years. For the cognitive assessment arm, 1089 participants from the original study were recruited at year 8 or 9 of follow-up and undertook 2 or 3 cognitive assessments, that evaluated verbal learning, memory, speed of processing, executive function and global cognitive functioning.

There was an equal number of participants from the ILI and DSE groups; the mean age of both samples was 58 years, and 42% of both groups was male and roughly 10% had pre-existing cardiovascular disease. Improvements in blood sugar control was associated with greater improvements in cognitive scores for most measures. In contrast, the association between improvements in weight loss and cognitive scores was less clear and depended to some extent, on the cognitive measure.

The authors were unable to account for these findings and concluded that any improvements in cognitive function were largely dependent on baseline levels of adiposity and cardiovascular disease history.

Carmichael OT et al. Long-term change in physiological markers and cognitive performance in type 2 diabetes: the look AHEAD trial. J Clin Endrocrinol Metab 2020; doi:10.1210/clinem/dgaa591